Engineering

Chromatography

Cyclodextrin

Biochemistry

Computer science

Solubilization

Stereochemistry

Mechanical engineering

Combinatorial chemistry

Pharmacology

Medicine

Chemistry

Stabilizer (aeronautics)

International Journal of Pharmaceutics

This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution.

Sulfobutylether-β-cyclodextrin